IDEAYA Biosciences (IDYA) Change in Accured Expenses (2018 - 2026)

IDEAYA Biosciences has disclosed Change in Accured Expenses across 9 years of filings, most recently posting $2.7 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $2.7 million, down 5.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.3 million (down 31.21% YoY), and the FY2025 annual result was $10.4 million, down 3.4% from the prior year.
• Change in Accured Expenses came in at $2.7 million for Q1 2026 at IDEAYA Biosciences, up from -$4.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $7.5 million in Q3 2025 to a low of -$4.8 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is $2.4 million (2023), against an average of $1.8 million.
• Peak annual rise in Change in Accured Expenses reached 668.11% in 2023, while the deepest fall reached 399.29% in 2023.
• IDEAYA Biosciences' Change in Accured Expenses stood at $323000.0 in 2022, then surged by 668.11% to $2.5 million in 2023, then fell by 8.34% to $2.3 million in 2024, then plunged by 311.04% to -$4.8 million in 2025, then soared by 156.82% to $2.7 million in 2026.
• The last three Change in Accured Expenses figures came in at $2.7 million (Q1 2026), -$4.8 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.